Group One Trading
RVNC

Group One Trading’s Revance Therapeutics, Inc. RVNC Stock Holding History

Group One Trading’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-170,900
Closed -$520K – 8581
2024
Q4 		$520K Buy
170,900
+92,400
+118% +$402K ﹤0.01% 3143
2024
Q3 		$407K Sell
78,500
-60,800
-44% -$302K ﹤0.01% 3016
2024
Q2 		$358K Sell
139,300
-27,200
-16% -$92.9K ﹤0.01% 2872
2024
Q1 		$819K Buy
166,500
+9,300
+6% +$55K ﹤0.01% 2267
2023
Q4 		$1.38M Buy
157,200
+95,300
+154% +$781K ﹤0.01% 2160
2023
Q3 		$710K Buy
61,900
+25,500
+70% +$490K ﹤0.01% 2587
2023
Q2 		$921K Buy
36,400
+16,300
+81% +$508K ﹤0.01% 2435
2023
Q1 		$647K Sell
20,100
-27,400
-58% -$854K ﹤0.01% 2517
2022
Q4 		$877K Sell
47,500
-88,400
-65% -$2.02M ﹤0.01% 2536
2022
Q3 		$3.67M Buy
135,900
+109,400
+413% +$2.22M 0.01% 1411
2022
Q2 		$366K Buy
26,500
+6,600
+33% +$102K ﹤0.01% 3711
2022
Q1 		$388K Buy
19,900
+3,800
+24% +$57.6K ﹤0.01% 4092
2021
Q4 		$263K Sell
16,100
-33,200
-67% -$553K ﹤0.01% 4799
2021
Q3 		$1.37M Buy
49,300
+41,400
+524% +$1.18M ﹤0.01% 3055
2021
Q2 		$234K Buy
7,900
+6,300
+394% +$182K ﹤0.01% 5064
2021
Q1 		$45K Sell
1,600
-34,800
-96% -$963K ﹤0.01% 6307
2020
Q4 		$1.03M Buy
36,400
+31,600
+658% +$819K ﹤0.01% 2611
2020
Q3 		$121K Sell
4,800
-5,800
-55% -$152K ﹤0.01% 4064
2020
Q2 		$259K Buy
10,600
+3,600
+51% +$71.1K ﹤0.01% 3170
2020
Q1 		$104K Buy
7,000
+6,500
+1,300% +$134K ﹤0.01% 3270
2019
Q4 		$8K Sell
500
-32,900
-99% -$510K ﹤0.01% 4664
2019
Q3 		$434K Buy
+33,400
New +$409K ﹤0.01% 2450
2019
Q2 		– Sell
-500
Closed -$8K – 5482
2019
Q1 		$8K Buy
500
+100
+25% +$1.73K ﹤0.01% 4348
2018
Q4 		$8K Sell
400
-19,400
-98% -$427K ﹤0.01% 4357
2018
Q3 		$492K Buy
19,800
+8,600
+77% +$234K ﹤0.01% 2300
2018
Q2 		$307K Buy
11,200
+5,000
+81% +$150K ﹤0.01% 2707
2018
Q1 		$191K Sell
6,200
-13,000
-68% -$418K ﹤0.01% 2830
2017
Q4 		$686K Buy
19,200
+18,900
+6,300% +$543K ﹤0.01% 1996
2017
Q3 		$8K Hold
300
– – ﹤0.01% 4368
2017
Q2 		$8K Sell
300
-100
-25% -$2.23K ﹤0.01% 4297
2017
Q1 		$8K Buy
+400
New +$8.22K ﹤0.01% 4186
2016
Q4 		– Sell
-100
Closed -$2K – 4908
2016
Q3 		$2K Sell
100
-2,000
-95% -$29K ﹤0.01% 4386
2016
Q2 		$29K Sell
2,100
-100
-5% -$1.77K ﹤0.01% 3618
2016
Q1 		$38K Sell
2,200
-4,900
-69% -$99.7K ﹤0.01% 3419
2015
Q4 		$243K Buy
7,100
+600
+9% +$20.8K ﹤0.01% 2355
2015
Q3 		$193K Buy
6,500
+1,000
+18% +$30.4K ﹤0.01% 2526
2015
Q2 		$176K Buy
5,500
+1,300
+31% +$33.4K ﹤0.01% 2628
2015
Q1 		$87K Buy
+4,200
New +$72.6K ﹤0.01% 2987

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Group One Trading's RVNC Position: Q1 2025 in Review

Group One Trading sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 92,379 shares — an estimated $281K sold.

Group One Trading first reported a position in RVNC in Q1 2015 and held it in 28 quarters. The position peaked at $2.22M in Q4 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Group One Trading reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Group One Trading sold 92,379 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $281K.
  • Group One Trading first reported a position in Revance Therapeutics, Inc. in Q1 2015 and held it in 28 quarters.
  • Group One Trading's Revance Therapeutics, Inc. position peaked at $2.22M in Q4 2022.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Group One Trading's 13F filing for Q1 2025, filed 14 May 2025.